Page last updated: 2024-08-23

perfosfamide and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

perfosfamide has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T	1

Other Studies

1 other study(ies) available for perfosfamide and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

Article	Year
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PloS one, 2014, Volume: 9, Issue:3 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab	2014

Article

Year

Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.

PloS one, 2014, Volume: 9, Issue:3

Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab

2014